The company will further develop its high-resolution spinal cord stimulation focal pain therapy and perform clinical studies

Transforming the Health and Life Sciences Industry with the Right Data. Find the Company's Curated Datasets on Amazon's New Platform.

Celebrating success across life sciences

Azzur Welcomes Tita Tavares as Director of Its New Office in Washington, D.C.

Announces Completion of Series B Financing

Industry Boosted by Reclassification of Prescription Drugs

The report commences with a scope of the global cannabidiol supplements market that includes the key findings and vital statistics of the market. This market research report also consists of the market value of the major segments of the global cannabidiol supplements market.

Preclinical results support the therapeutic potential of KB-1801 for the prevention of Cardiac Surgery-Associated Acute Kidney Injury and advancement into clinical development

Hardy Diagnostics, providing the latest designs from Orum International, of Milan, Italy.

BillionToOne and Eluthia have announced today the launch of the first and only non-invasive prenatal test, allowing to screen for the autosomal-recessive conditions cystic fibrosis, spinal muscular atrophy (SMA), sickle cell disease and other hemoglobinopathies. The UNITY™ screen will be made available through Eluthia in Germany, Austria, Switzerland, and the Netherlands, as of now.

MultiTEP Platform-Based Epitope Vaccine Targeting the Phosphatase Activating Domain (PAD) of Tau Shows Clear Therapeutic Efficacy in PS19 Mice

Cambridge Isotope Laboratories, Inc. (CIL) board of directors appointed Cliff Caldwell as its new chief executive officer (CEO), as Joel Bradley, founder and CEO, stepped down from his position after 38 years.

Jubilant Radiopharma announced today that its Radiopharmacies Division has been awarded the group purchasing agreement by Premier Inc. for its full line of radiopharmaceuticals products.

Telephonic Health Coaching the Fastest-Growing Segment of the Industry

Industry Boosted by Aging Population and Improved Drug Therapy

Parnell announces a new contract manufacturing agreement for one animal health product and a memorandum of understanding for two additional products with a global multi-national; revenue in the first half of 2019 down 12% compared to 2018 due to timing of technology transfer revenues versus prior year; and holds 2019 guidance for a 17 - 25% increase over 2018 revenue and an EBITDA range of $7.5 - $8.5m.

Appointment reflects Glauconix Biosciences' readiness to expand their commercial footprint and business verticals in the field of ophthalmology and beyond